No CrossRef data available.
Article contents
Switching from SSRIs to Nefazodone: Three Case Reports
Published online by Cambridge University Press: 07 November 2014
Abstract
An abstract is not available for this content so a preview has been provided. Please use the Get access link above for information on how to access this content.
- Type
- Grand Rounds—Case Reports
- Information
- Copyright
- Copyright © Cambridge University Press 1997
References
1.Preskorn, SH.Comparison of the tolerability of nefazodone, imipramine, fluoxetine, sertraline, paroxetine, and venlafaxine. J Clin Psychiatry. 1995;56(suppl 6):12–21.Google ScholarPubMed
2.Castaneda, R, Levy, R, Westreich, L, Sussman, N. Drug craving and other negative reactions after abrupt substitution of nefazodone for other serotonergic agents (Letter). J Clin Psychiatry. 1996:57:485–486.Google Scholar
3.Benjamin, J, Greenberg, BD, Murphy, DL. Daily administration of m-chlorophenylpiperazine to healthy human volunteers rapidly attenuates many of its behavioral, hormonal, cardiovascular and temperature effects. Psycho-pharmacology. 1996;127:140–149.CrossRefGoogle ScholarPubMed
4.Germine, M, Goddard, AW, Sholomskas DE, Woods SW, Charney DS, Henninger GR. Response to meta-chlorophenylpiperazine in panic disorder patients and healthy subjects: influence of reduction in intravenous dosage. Psychiatry Res. 1994;54:115–133.CrossRefGoogle Scholar
5.Germine, M, Goddard, AW, Woods, SW, Charney, DS, Henninger, GR. Anger and anxiety responses to mchlorophenylpiperazine in generalized anxiety disorder. Biol Psychiatry. 1992;32:457–461.CrossRefGoogle ScholarPubMed
6.Charney, DS, Woods, SW, Goodman, WK, Henninger, GR. Serotonin function in anxiety. II. Effects of the serotonin agonist mCPP in panic disorder patients and healthy subjects. Psychopharmacology. 1987;92:14–24.CrossRefGoogle ScholarPubMed
7.Pigott, TA, Hill, JL, Grady, TA, et al.A comparison of the behavioral effects of oral versus intravenous m-CPP administration in OCD patients and the effects of metergoline prior to IVmCPP. Biol Psychiatry. 1993;33:3–14.CrossRefGoogle Scholar
8.Stein, DJ, Hollander, E, DeCaria, CM, Simeon, D, Cohen, L, Aronowitz, B. m-Chlorophenylpiperazine challenge in borderline personality disorder: relationship of neuroendocrine response, behavioral response, and clinical measures. Biol Psychiatry. 1996;40:508–513.CrossRefGoogle ScholarPubMed
9.Krystal, JH, Webb, E, Cooney, N, Kranzler, HR, Charney, DS. Specifity of ethanol-like effects elicited by serotonergic and noradrenergic mechanisms. Arch Gen Psychiatry. 1994;51:898–911.CrossRefGoogle Scholar
10.Walsh, AE, Hockney, RA, Campling, G, Cowen, PJ. Neuroendocrine and temperature effects of nefazodone in healthy volunteers. Biol Psychiatry. 1993;33:115–119.CrossRefGoogle ScholarPubMed
11.Bonson, KR, Buckholtz, JW, Murphy, DL. Chronic administration of serotonergic antidepressants attenuates the subjective effects of LSD in humans. Neuropsycho-pharmacology. 1996;14:425–436.CrossRefGoogle ScholarPubMed
12.Kahn, RS, Davidson, M, Siever, LJ, Sevy, S, Davis, KL. Clozapine treatment and its effect on neuroendocrine responses induced by the serotonergic agonist m-chlorophenylpiperazine. Biol Psychiatry. 1994;35: 909–912.CrossRefGoogle Scholar
13.Laakso, A, Palvimaki, E-P, Kuoppamaki, M, Syvalahti, E, Hietala, J. Chronic citalopram and fluoxetine treatments upregulate 5-HT2C receptors in the rat choroid plexus. Neuropsychopharmacology. 1996;15:143–151.CrossRefGoogle ScholarPubMed
14.Palvimaki, E-P, Roth, BL, Majasuo, H, et al. Interactions of selective serotonin reuptake inhibitors with the serotonin 5-HT2C receptor. Psychopharmacology. 1996:126: 234–240.CrossRefGoogle ScholarPubMed
15.Wong, DT, Threlkeld, PG, Robertson, DW. Affinities of fluoxetine, its enanthomers, and other inhibitors of serotonin uptake for subtypes of serotonin receptors. Neuropsychopharmacology. 1991;5:43–47.Google ScholarPubMed
16.Maj, J, Bijak, M, Dziedzicka-Wasylewska, M, et al.The effects of paroxetine given repeatedly on the 5-HT receptor subpopulations in the rat brain. Psychopharmacology. 1996;127:78–82.CrossRefGoogle ScholarPubMed
17.Hollander, E, Decaria, CM, Gulley, R, et al.Effects of chronic fluoxetine on behavioral and neuroendocrine response to meta-chlorophenyldiperazine in obsessive-compulsive disorder. Psychiatry Res. 1991;36:1–17.CrossRefGoogle ScholarPubMed
18.Barbhaiya, RH, Shukla, UA, Natarajan, CS, Behr, DA, Greene, DS, Sainati, SM. Single- and multiple-dose pharmacokinetics of nefazodone in patients with hepatic cirrhosis. Clin Pharmacol Therapeut. 1995;58:390–398.CrossRefGoogle ScholarPubMed
19.Tecott, LH, Sun, LM, Akana, SF, et al.Eating disorders and epilepsy in mice lacking 5-HT2C serotonin receptors. Nature. 1995;374:542–546.CrossRefGoogle ScholarPubMed
20.Pigott, TA, Zohar, J, Hill, JL, et al.Metergoline blocks the behavioral and norendocrine effects of orally administered meta-chlorophenyldiperazine in patients with obsessive-compulsive disorder. Biol Psychiatry. 1991;29:418–426.CrossRefGoogle ScholarPubMed